NextCell Pharma AB (STO:NXTCL)

Market Cap	116.96M +53.9%
Revenue (ttm)	9.24M -2.2%
Net Income	-41.58M
EPS	n/a
Shares Out	111.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	257,464
Open	1.092
Previous Close	1.100
Day's Range	1.032 - 1.100
52-Week Range	0.630 - 1.784
Beta	0.69
Analysts	n/a
Price Target	3.50 (0.0%)
Earnings Date	May 28, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 24
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NXTCL

Financial Performance

In 2025, NextCell Pharma AB's revenue was 9.83 million, a decrease of -11.13% compared to the previous year's 11.06 million. Losses were -38.79 million, 10.4% more than in 2025.